unknown
Stage
About
Anida Pharma is developing first-in-class therapeutics that leverage endogenous protective mechanisms to prevent progressive eye diseases. Its lead candidate, AP-001, is a modified form of neuroprotectin D1 designed for topical ocular administration (eye drops) to treat corneal and retinal degenerative conditions.
Explore Anida Pharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.